At the news
? BULLISHIMPACT 8/10 8-K filed Jun 1, 2026 at 08:51 ET
Edgewise Therapeutics announced an asset purchase agreement to sell its neuromuscular program, including the sevasemten compound, to Servier for $1.55 billion in upfront cash, plus up to $1.1 billion in regulatory and commercial milestones. The transaction transforms Edgewise into a cardiovascular-focused company, with proceeds expected to fully fund EDG-7500 development through potential approval. The deal is expected to close in Q3 2026, subject to HSR clearance and customary conditions.
- Edgewise sells sevasemten and related neuromuscular assets to Servier for $1.55 billion upfront cash.
- Potential milestone payments up to $1.1 billion: $200M or $100M for Becker approval, $600M for Duchenne approval, $300M for sales milestone.
- Proceeds fully fund EDG-7500 development through potential approval and strengthen the balance sheet.
- Edgewise becomes a pure-play cardiovascular company focused on EDG-7500 (Phase 2 HCM), EDG-15400 (Phase 1 HFpEF), and EDG-003 (preclinical).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access